Conversation has moved to delivery: the call's center of gravity is how and when real business converts, not whether it
The model's full reasoning — Q3 2016 call → NOThe question asks whether the center of gravity of the discussion has moved past whether demand exists and onto the practical mechanics of converting real business into delivered results. Let me analyze the transcript: 1. The call covers multiple programs: margetuximab (Phase 3 SOPHIA trial), enoblituzumab (B7-H3 franchise), MGD009, MGD006, MGD007, MGD011 (partnered with Janssen), PF-06671008 (partnered with Pfizer), MGD010 (autoimmune), MGD014 (infectious disease), MGD013, MGA012. 2. Are these programs "real business" with actual current activity? The programs are in clinical trials — Phase 1, Phase 2, Phase 3. The company is enrolling patients, activating sites, advancing dose cohorts. This is actual current work — clinical trials are the "business" of a biotech at this stage. The trials are ongoing, patients are being enrolled, sites activated. 3. Is the dialogue about conversion mechanics? The analysts ask about: - Enrollment in SOPHIA trial and timing of interim analysis - Fraction of patients from Europe vs US - Catalysts at ASH - Licensing partnership discussions - MGD010 immunological information - MGD006 read-through from J&J hold - gpA33 dosing - B7-H3 combo dosing Management answers with specifics about enrollment progress, site activation (90%), dose escalation cohorts, timing of data readouts, R&D Day presentations. However, is this "converting real business into delivered results"? For a biotech, the "business" is clinical development. The trials are ongoing, but the question is whether the discussion is about converting already-won business into results, or about pipeline development. The company is a clinical-stage biotech. Its "business" is developing drugs. The trials are real and ongoing. But the question asks whether the discussion has moved past whether demand exists — for a biotech, "demand" would be whether the drugs work and get approved. The discussion is about trial mechanics, enrollment, dosing — this is the conversion of clinical development into data/results. But wait — is this "business that is ALREADY REAL"? The trials are real, patients are enrolling. But the ultimate product (approved drugs) is prospective. The question is whether the center of gravity is on converting real committed work into results. Actually, let me reconsider.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SU | Suncor Energy Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
GOLD · Q3 2023 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The transcript shows the center of gravity has shifted to execution mechanics for already-committed operations and growth projects. Management details current production (up QoQ at NGM, Loulo-Gounkoto, Kibali), specific ramp-up challenges and fixes at Pueblo Viejo (gearbox failures, conveyor issues, temporary 70-75% throughput solutions, new assemblages arriving end-2023), tailings permitting, and phased construction at RekoDiq/Lumwana (2025 start, 2028/2026 first production). Analysts press on Q4 production, 2024 profiles (PV >800koz despite delays), recovery rates 70% to design, capital sequencing ($2.5B 2024, peaks 2025-26), and conversion timing (downtimes, relocations, training).
LBTYK · Q1 2016 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The call as a whole satisfies both conditions. Management repeatedly frames the business as already real—existing customer bases, price increases already implemented across two-thirds of the footprint, 210,000 new-build homes added in Q1, 330,000 premises released under Project Lightning, 100,000 postpaid mobile subs added organically, BASE integration underway, and the Cable & Wireless transaction closing next week.
DXCM · Q4 2023 → YESThe question is: has the CENTER OF GRAVITY of the discussion visibly moved PAST the question of whether demand for the company's offering exists, and ONTO the practical mechanics of converting busines...